Axelia Oncology Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Series A
- Investors
-
3
Axelia Oncology General Information
Description
Operator of a biotechnology company intended to develop a fully synthetic TLR2/6 (toll-like receptors 2 and 6) specific innate immunomodulator. The company uses a district mechanism of action to treat solid tumors and harness the innate immune system to combat checkpoint-insensitive tumors, enabling medical professionals to create safe and effective therapies for cancer patients through the body's immune system.
Contact Information
Website
www.axeliaoncology.comCorporate Office
- Level 9, 31 Queen Street
- Melbourne, Victoria 3000
- Australia
Corporate Office
- Level 9, 31 Queen Street
- Melbourne, Victoria 3000
- Australia
Axelia Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC (Series A) | Completed | Pre-Clinical Trials |
Axelia Oncology Comparisons
Industry
Financing
Details
Axelia Oncology Competitors (4)
One of Axelia Oncology’s 4 competitors is Tallac Therapeutics, a Venture Capital-Backed company based in Burlingame, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Tallac Therapeutics | Venture Capital-Backed | Burlingame, CA | ||||
| TriSalus Life Sciences | Formerly VC-backed | Westminster, CO | ||||
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| EIKON Group | Private Equity-Backed | London, United Kingdom |
Axelia Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Axelia Oncology Patents
Axelia Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020904847-A0 | Branched lipid compounds | Inactive | 24-Dec-2020 | ||
| AU-2020902150-A0 | Coronavirus treatment (2) | Inactive | 26-Jun-2020 | ||
| AU-2020902151-A0 | Treatment of coronavirus (2) | Inactive | 26-Jun-2020 | ||
| AU-2020901709-A0 | Coronavirus treatment | Inactive | 26-May-2020 | ||
| AU-2020901711-A0 | Treatment of coronavirus | Inactive | 26-May-2020 |
Axelia Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Axelia Oncology Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Brandon Capital | Venture Capital | Minority | ||
| Stoic Venture Capital | Venture Capital | Minority | ||
| Uniseed | Venture Capital | Minority |
Axelia Oncology FAQs
-
When was Axelia Oncology founded?
Axelia Oncology was founded in 2014.
-
Where is Axelia Oncology headquartered?
Axelia Oncology is headquartered in Melbourne, Australia.
-
What is the size of Axelia Oncology?
Axelia Oncology has 5 total employees.
-
What industry is Axelia Oncology in?
Axelia Oncology’s primary industry is Drug Discovery.
-
Is Axelia Oncology a private or public company?
Axelia Oncology is a Private company.
-
What is Axelia Oncology’s current revenue?
The current revenue for Axelia Oncology is .
-
Who are Axelia Oncology’s investors?
Brandon Capital, Stoic Venture Capital, and Uniseed have invested in Axelia Oncology.
-
Who are Axelia Oncology’s competitors?
Tallac Therapeutics, TriSalus Life Sciences, Regeneron Pharmaceuticals, and EIKON Group are competitors of Axelia Oncology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
